Evidence map›Paper›PMID 27142767›Full record

ArticleIn vitro cellular & developmental biology. Animal2016

Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.

He-Yi You, Xue-Meng Xie, Wei-Jian Zhang, Heng-Liang Zhu, Fei-Zhao Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology. Animal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Current Advances inFrontiers in pharmacology · 2021
    Review
  19. Article
  20. Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

He-Yi YouDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. yheyi2016@126.com.
Xue-Meng XieDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Wei-Jian ZhangDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Heng-Liang ZhuDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Fei-Zhao JiangDepartment of Laparoscopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
First Affiliated Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapeutic resistance is the main reason of the failure in clinical treatment of gastric cancer. Berberine (BER) is the active compound of traditional Chinese medicine Huang Lian. The aim of this present study is to evaluate the effect of BER on cisplatin resistance in gastric cancer cells and to investigate its possible mechanism. Gastric cancer cell lines SGC-7901 and BGC-823 and their respective cisplatin-resistant variants SGC-7901/DDP and BGC-823/DDP were used in this study. We found that BER treatment significantly reversed cisplatin sensitivity and induced caspase-dependent apoptosis in SGC-7901/DDP and BGC-823/DDP cells; BER treatment induced miR-203 expression, and overexpression of miR-203 mimicked the cisplatin-sensitizing effect of BER. Importantly, we showed that miR-203 was able to target the 3'UTR of Bcl-w. Therefore, we conclude that BER treatment reduces cisplatin resistance of gastric cancer cells by modulating the miR-203/Bcl-w apoptotic axis. BER may be a novel agent to enhance chemotherapeutic responses in cisplatin-resistant gastric cancer patients.

Indexed as

ApoptosisApoptosis Regulatory ProteinsBerberineCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMicroRNAsStomach NeoplasmsApoptosis Regulatory ProteinsBCL2L2 protein, humanBerberineCisplatinMicroRNAsMIRN203 microRNA, humanApoptosisBcl-wBerberineGastric cancerMicroRNA-203

Identifiers

PMID27142767
OpenAlexW2346343319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.